Sleep · 2022
The "Dream Changer": a randomized controlled trial evaluating the efficacy of a parent-based intervention for childhood nightmares.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bourboulis Stephanie, Gradisar Michael, Kahn Michal
Аннотация
STUDY OBJECTIVES: Recurrent nightmares in childhood may have a range of detrimental effects for both the child and parents. This randomized controlled trial evaluated the efficacy of a novel parent-based intervention for childhood nightmares, using a new device called the "Dream Changer."
METHODS: A total of 56 children aged 3-10 years (M = 7.1 ± 2.1 years; 51.8% boys), and one of their parents were randomized to either the intervention or waitlist control group. The intervention group received a "Dream Changer"-a light-emitting remote-control-like device that the child was encouraged to take to bed and use upon experiencing a nightmare. Parents completed online surveys at baseline, 1-week, and 2-weeks following the intervention. Parents in the intervention group additionally completed a 3-month follow-up survey. Outcome variables included children's nightmare frequency, sleep-wake patterns, and sleep anxiety, as well as parents' daytime sleepiness.
RESULTS: Significant group-by-time interaction effects were found for nightmare frequency (p = 0.001) and sleep anxiety (p = 0.006). Parents of children who received the "Dream Changer" reported fewer nightmares (Mdifference = 1.7, p < 0.001, d = 1.06) and decreased anxiety (Mdifference = 0.9, p = 0.001, d =0.41) at post-intervention, whereas such benefits were not found in the waitlist control group. Three-month follow-up assessments demonstrated that gains were maintained over-time. Interaction effects were not significant for children's sleep metrics or for parents' daytime sleepiness.
CONCLUSIONS: The present study provides preliminary evidence for the efficacy of a brief, highly accessible intervention for reducing children's nightmares and nighttime anxiety. Future research may wish to test these effects using larger samples and longer follow-up assessments.
CLINICAL TRIAL REGISTRATION: The trial has been registered at the Australian New Zealand Clinical Trials Registry (https://www.anzctr.org.au/; Identifier:ACTRN12620000633987).
METHODS: A total of 56 children aged 3-10 years (M = 7.1 ± 2.1 years; 51.8% boys), and one of their parents were randomized to either the intervention or waitlist control group. The intervention group received a "Dream Changer"-a light-emitting remote-control-like device that the child was encouraged to take to bed and use upon experiencing a nightmare. Parents completed online surveys at baseline, 1-week, and 2-weeks following the intervention. Parents in the intervention group additionally completed a 3-month follow-up survey. Outcome variables included children's nightmare frequency, sleep-wake patterns, and sleep anxiety, as well as parents' daytime sleepiness.
RESULTS: Significant group-by-time interaction effects were found for nightmare frequency (p = 0.001) and sleep anxiety (p = 0.006). Parents of children who received the "Dream Changer" reported fewer nightmares (Mdifference = 1.7, p < 0.001, d = 1.06) and decreased anxiety (Mdifference = 0.9, p = 0.001, d =0.41) at post-intervention, whereas such benefits were not found in the waitlist control group. Three-month follow-up assessments demonstrated that gains were maintained over-time. Interaction effects were not significant for children's sleep metrics or for parents' daytime sleepiness.
CONCLUSIONS: The present study provides preliminary evidence for the efficacy of a brief, highly accessible intervention for reducing children's nightmares and nighttime anxiety. Future research may wish to test these effects using larger samples and longer follow-up assessments.
CLINICAL TRIAL REGISTRATION: The trial has been registered at the Australian New Zealand Clinical Trials Registry (https://www.anzctr.org.au/; Identifier:ACTRN12620000633987).